- Details
- In this discussion, Susan Slovin and Alicia Morgans discuss the incorporation of PSMA PET imaging and emerging treatments like lutetium-177-PSMA in genitourinary oncology. Referencing ASCO 2022 talks and clinical trials, particularly Dr. Mike Hofman's study comparing lutetium-PSMA and cabazitaxel post-docetaxel, they review three-year data showing no significant difference in overall survival betw...
|
- Details
- Alicia Morgans speaks with Oliver Sartor about the SPLASH trial and advances in radioligand therapy. The SPLASH trial involves PSMA I&T Lutetium-177 (renamed PNT2002) for pre-chemo, metastatic CRPC patients, with some differences in dose and schedule compared to PSMA 617. In the lead-in study involving 27 PSMA PET-selected patients, the initial PSA 50 response rate was 40%, and the radiographic re...
|
- Details
- Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...
|
- Details
- Vivek Narayan joins Alicia Morgans at ASCO 2022 to discuss his work with CAR T-cell therapies and prostate cancer, the first-in-human study. Using a low-dose escalation approach, Dr. Narayan and his team designed the study safety as the primary objective to evaluate the feasibility of manufacturing and delivering the CAR T-cells. He describes how findings showed both on-treatment toxicity and on-t...
|
- Details
- Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Dr. Morgans shares her thoughts on the importance of collaboration across teams in treating patients with GU cancers and provides an overview of key content in the book. Biographies: Alicia Morgans, MD, MPH , Genitourinary...
|
- Details
- Clara Hwang shares an overview of her ASCO 2022 poster session presentation with Alicia Morgans. Dr. Hwang explains how the research was motivated by the known disparities in Black versus white men regarding prostate cancer diagnosis and prognosis. She then describes how this study explored these disparities within the prostate cancer precision medicine space. Biographies: Clara Hwang, MD, Medical...
|
- Details
- Phil Kantoff, CEO of Convergent Therapeutics, sits down with Alicia Morgans to discuss the future of radioligand therapy in the treatment of advanced prostate cancer. Philip Kantoff provides an overview of exciting results seen in studies on actinium-225, a powerful alpha-emitter tested in patients with advanced prostate cancer that also may be promising for patients with earlier-stage disease. Bi...
|
- Details
- Alicia Morgans and Matthew Smith join Charles Ryan to discuss cancer survivorship. Drs Morgans and Smith explain the holistic role that a cancer survivorship program plays in the health and well-being of prostate cancer patients, including bone health, mental health, monitoring cardiovascular risk, and more. Biographies: Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, A...
|
- Details
- Channing Paller joins Alicia Morgans at ASCO 2022 to discuss considerations in the timing and intensity of ADT in biochemical recurrence. Dr. Paller gives an overview of her presentation and the two explore important considerations when timing treatment for prostate cancer after recurrence and relevant clinical trial data, such as TOAD and CRUK. In addition, they acknowledge the importance of pati...
|
- Details
- Alicia Morgans interviews Nicholas James about the RADICALS trial, a complex study aiming to determine the optimal timing for radiotherapy after surgery and the amount of hormone therapy needed. The first question's data showed that waiting was safe and adjuvant therapy unnecessary. The second question, presented at ESMO, involved pragmatic randomization between zero, six, and 24 months of ADT, re...
|
